Volume 5 Supplement 8
Use of Micro Bioreactor systems to streamline cell line evaluation and upstream process development for monoclonal antibody production
© Warr et al; licensee BioMed Central Ltd. 2011
Published: 22 November 2011
The development of monoclonal antibody (mAb) processes conventionally involves the generation of multiple cell lines in multiwell plates, cell line screening in shake flasks followed by final cell line selection and process optimisation in bioreactors. This process can typically take up to 18 months to generate a robust process suitable for early phase manufacturing and therefore any opportunity to streamline this process impacts directly on drug development timelines.
This work describes the potential integration of the Micro-24 Bioreactor system (Pall Life Sciences) and the Duetz Microflask system (Applikon Biotechnology) into cell line development and early process development and demonstrates how these systems can be used for cell line evaluation and process optimisation. The Micro-24 Bioreactor system comprises 24 bioreactors (7ml working volume) each capable of independent temperature, dissolved oxygen and pH control. Cell cultures are carried out in a presterilised polycarbonate mammalian cell culture cassette with a central vent and are inoculated manually in a laminar flow cabinet before sealing with Type A single use closures and incubation under experimental conditions.
The performance of a number of cell lines in the Micro-24 Bioreactor and the Duetz Microflask system was compared to that in shake flasks and bioreactors using cell numbers, viability and product titre. This data was then used to rank cell lines according to specific parameters. Unless otherwise stated a standard hydrolysate containing complex medium and standard experimental conditions were used throughout this work. For shake flasks these were: 35°C, 5% CO2, 140 rpm; for Duetz Microflasks: 35°C, 5% CO2, 200 rpm, 80% humidity and for Micro-24 Bioreactors: 35°C, 650rpm, 6.95 pH, 30% DO. Viable cell numbers and viability were determined using a ViCell Cell Viability Analyser (Beckman Coulter) and antibody titres were determined using an Immunochemistry System (Beckman Coulter).
A hydrolysate containing complex media fed batch process was run in each of the 24 bioreactors using the same model CHO cell line. Viable cell numbers (VCC), viability and titre were measured in each bioreactor and the coefficients of variation (CV) were calculated for each time point. This data was also used to calculate the specific productivity (SPR) for each bioreactor. At each time point CVs were generally less than 10% for each parameter measured and there was no significant difference between different rows of the cassette.
Cell Line Selection
To demonstrate the potential of this system to identify candidate mAb producing cell lines a series of experiments was carried out using the Micro-24 Bioreactor system and the results compared to those obtained in our standard cell line selection process. After initial screening in static multiwell plates during scale up a further screen in the Duetz Microflask system indicated significant differences in the performance of the remaining cell lines. In the standard hydrolysate containing batch process peak titres varied by up to 60% and there was a 2 fold difference in the overall SPR across the different cell lines.
Based on titre and SPR data from the Duetz Microflask screen 12 of these cell lines were selected for further evaluation. Using the standard batch process conditions these cell lines were grown in parallel in the Micro-24 Bioreactors, Duetz Microflasks and conventional shake flasks. Although there were some differences in absolute titres the rank order of cell lines was similar in each of the systems tested here (Figure 1a and b) with R2=0.66 (Micro-24 v Duetz) and R2=0.72 (Micro-24 v shake flasks).The rank order of peak VCC was also similar in the Micro-24 and shake flasks (R2 = 0.7) although there was less similarity in overall SPR (R2 = 0.4).
This data from the batch process was used to select 6 cell lines for evaluation in the standard fed batch process which was run in parallel in the Micro-24 Bioreactor and shake flasks.
Clones ranked 1, 2, 5 and 12 in the Micro-24 Bioreactors were tested in conventional 2 litre bioreactors. In bioreactors the titre produced by the top ranked clone was approximately 20% higher than the clone ranked 12. The remaining 2 clones (ranked 2 and 5 in the Micro-24) produced intermediate titres.
SEC, CE-IEF and NGHC data for the mAb produced in the Micro-24 showed no significant differences to that produced in control shake flasks.
Table 1A – Medium Development
Shake flasks (120mL)
Table 1B – Condition Optimisation
This data demonstrates that the Micro-24 Bioreactor can be used successfully to select high producing cell lines and to carry out initial process optimisation experiments. Although there were some differences in absolute data the rank orders and process trends identified in the Micro-24 Bioreactors were similar to those in conventional systems. Therefore this work has shown that the Micro-24 Bioreactor system could be used to replace shake flasks and bioreactors in cell line evaluation and early process improvement work.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.